Patents by Inventor Michael Bukys

Michael Bukys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR MAINTAINING AGGREGATE STABILITY AND PLURIPOTENCY OF STEM CELLS
    Publication number: 20250011726
    Abstract: Methods for maintaining aggregate stability and pluripotency of human stem cells are provided using chemically-defined culture media that includes heparin sodium salt and polyethylene glycol. Methods of modulating aggregate size and/or stability using chemically-defined culture media are also provided. The methods can be used with, for example, induced pluripotent stem cells or embryonic stem cells. Culture media and kits are also provided.
    Type: Application
    Filed: July 3, 2024
    Publication date: January 9, 2025
    Inventors: Michael BUKYS, Haneen YEHYA
  • GENERATING HUMAN PODOCYTE CELLS
    Publication number: 20240309332
    Abstract: Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 19, 2024
    Inventors: Oliver Wessely, Uyen Wessely, Jan Jensen, Michael Bukys
  • Generating human podocyte cells
    Patent number: 12018286
    Abstract: Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 25, 2024
    Assignee: The Cleveland Clinic Foundation
    Inventors: Oliver Wessely, Uyen Wessely, Jan Jensen, Michael Bukys
  • COMPOSITIONS AND METHODS FOR SMALL MOLECULE BASED EXPANSION OF PLURIPOTENT STEM CELLS
    Publication number: 20240117302
    Abstract: Methods and composition for growth and maintenance of Oct3/4+ SOX2+ NANOG+ pluripotent stem cells (PSCs) or generation and maintenance of CD7+ CD75+ CD77+ CD130+ F11R+ naïve PSCs in cell culture comprise the use of a small molecule-based culture media comprising an Akt pathway agonist, an FGFR pathway agonist, a JAK/STAT pathway antagonist, a PKC pathway antagonist, and an AMPK pathway agonist.
    Type: Application
    Filed: October 6, 2023
    Publication date: April 11, 2024
    Inventor: Michael BUKYS
  • METHODS AND COMPOSITIONS FOR SMALL MOLECULE BASED PANCREATIC BETA CELL INDUCTION
    Publication number: 20240067931
    Abstract: Methods and compositions for generating human pancreatic beta cells, and the progenitor cells thereof, from human pluripotent stem cells using chemically defined culture media are disclosed. The methods allow for the initial generation of FOXA2+HNF1b+ dorsal foregut endodermal cells (DFECs), which can be further differentiated to human PTF1A+PDX1+ pancreatic progenitor cells (PPCs) and human INS+PDX+ pancreatic beta cells (PBCs) according to the methods provided. Culture media, isolated cell populations and kits are also provided.
    Type: Application
    Filed: August 23, 2023
    Publication date: February 29, 2024
    Inventor: Michael BUKYS
  • GENERATING HUMAN PODOCYTE CELLS
    Publication number: 20210079357
    Abstract: Provided herein are compositions, systems, kits, and methods for generating human podocyte cells by contacting human nephron progenitor cells with an FGFR pathway inhibitor, a BMP pathway inhibitor, and a WNT pathway inhibitor. In certain embodiments, the nephron progenitor cells are further contacted with at least one factor selected from: BMP4, BMP7, lysophosphatidic acid, and gamma-secretase inhibitor XX. In certain embodiments, the contacting the nephron progenitor cells is performed under serum-free conditions.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 18, 2021
    Inventors: Oliver Wessely, Uyen Wessely, Jan Jensen, Michael Bukys